Cargando…
Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months
Autores principales: | Noor, Ramadhani A, Thiesen, Michael, Mordmuller, Benjamin, Milligan, Paul, Atuguba, Frank, Sirima, Sodiomon, Issifou, Saadou, Bojang, Kalifa, Kironde, Fred, Tiono, Alfred, Okech, Brenda, Chilengi, Roma, Ngoa, Ateba, Mukasa, Kaddu, Jepsen, Soren |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963266/ http://dx.doi.org/10.1186/1475-2875-9-S2-P26 |
Ejemplares similares
-
A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children
por: Bélard, Sabine, et al.
Publicado: (2011) -
GMZ2 Vaccine-Induced Antibody Responses, Naturally Acquired Immunity and the Incidence of Malaria in Burkinabe Children
por: Dassah, Sylvester, et al.
Publicado: (2022) -
Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial
por: Nouatin, Odilon, et al.
Publicado: (2022) -
Malariometric indices from Iganga, Uganda: baseline characterization in preparation of GMZ2 vaccine trial
por: Kaddumukasa, Mark, et al.
Publicado: (2014) -
Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2009)